

Please type a plus sign (+) inside this box → [+]

JAN 07 2004

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number~~

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

lection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


SHEET 1 of 3

COMPLETE IF KNOWN	
Application Number	10/649,852
Confirmation Number	7224
Filing Date	August 27, 2003
First Named Inventor	Robert J. Isfort
Group Art Unit	
Examiner Name	
Attorney Docket Number	8448R

U. S. PATENT DOCUMENTS

EXAMINER INITIALS ¹	Cite No. ¹	U.S. PATENT DOCUMENT Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
SAB	1	5,844,074		Rivier	12/01/1998	
	2	5,663,292		Rivier	09/02/1997	
	3	5,235,036		Kornreich, et al.	09/10/1993	
	4	5,869,450		Wei, et al.	02/09/1999	
	5	5,824,771		Rivier	10/20/1998	

FOREIGN PATENT DOCUMENTS



Please type a plus sign (+) inside this box → [+]

PTO/SB08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


SHEET 2 of 3

COMPLETE IF KNOWN

Application Number	10/649,852
Confirmation Number	7224
Filing Date	August 27, 2003
First Named Inventor	Robert J. Isfort
Group Art Unit	
Examiner Name	
Attorney Docket Number	8448R

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
CKS	9	T.M. REYES, ET AL., "Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors", <i>PNAS</i> , February 27, 2001, 2843-2848, Vol. 98, No. 5, USA.	
CKS	10	E.B DE SOUZA, "Corticotropin-Releasing Factor Receptors: Physiology, Pharmacology, Biochemistry and Role In Central Nervous System and Immune Disorders", <i>Psychoneuroendocrinology</i> , 1995, 789-819, Vol. 20, No. 8, Elsevier Science Ltd., USA.	
CKS	11	D.T. CHALMERS, ET AL., "Corticotropin-releasing factor receptors: from molecular biology to drug design", <i>TiPS</i> , April 1996, 166-172, Vol. 17, Elsevier Science Ltd., USA	
CKS	12	H.A. THOMAS, ET AL., "CRF and Related Peptides as Anti-Inflammatory Agonists", <i>Annals New York Academy of Sciences</i> , 219-228. <i>VOLUME, year?</i>	
CKS	13	E.T. WEI, ET AL., "Peripheral anti-inflammatory actions of corticotropin-releasing factor", <i>Ciba Foundation Symposium</i> 172, 1993, 258-276, Wiley, Chichester.	
CKS	14	J.R. MCCARTHY, ET AL., "Recent Advances with the CRF ₁ Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications", <i>Current Pharmaceutical Design</i> , 1999, 289-315, Vol. 5, Bentham Science Publishers B.V.	
CKS	15	J.R. MCCARTHY, ET AL., "Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents", <i>Annual Reports in Medicinal Chemistry</i> , 11-20, Vol. 34, Academic Press. <i>Year?</i>	
CKS	16	G.P. CHROUSOS, ET AL., "Corticotropin Releasing Factor: Basic Studies and Clinical Applications", <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> , 1985, 349-359, Vol. 9, Pergamon Press Ltd., Great Britain.	
CKS	17	G.B. CUTLER, JR., M.D., "Corticotropin-Releasing Hormone (CRH): Clinical Studies and Use", <i>The Endocrinologist</i> , 1997, 10S-16S, Vol. 7, No. 1, Suppl. 1, Williams & Wilkins.	
CKS	18	M.J. OWENS, ET AL., "Physiology and Pharmacology of Corticotropin-releasing Factor", <i>Pharmacological Reviews</i> , 1991, 425-473, Vol. 43, No. 4, The American Society for Pharmacology and Experimental Therapeutics, USA.	
CKS	19	L. ARBORELIUS, ET AL., "The role of corticotropin-releasing factor in depression and anxiety disorders", <i>Journal of Endocrinology</i> , 1999, 1-12, Vol. 160, Society for Endocrinology, Great Britain.	
CKS	20	D.N. ORTH, "Corticotropin-Releasing Hormone in Humans", <i>Endocrine Reviews</i> , 1992, 164-191, Vol. 13, No. 2, The Endocrine Society, USA.	
CKS	21	E. EMERIC-SAUVAL, "Corticotropin-Releasing Factor (CRF) – A Review", <i>Psychoneuroendocrinology</i> , 1985, 277-294, Vol. 11, No. 3, Pergamon Journals Ltd., Great Britain.	
CKS	22	J. SPIESS, ET AL., "Molecular Properties of the CRF Receptor", <i>TEM</i> , 1998, 140-145, Vol. 9, No. 4, Elsevier Science Ltd.	
CKS	23	K.D. DIETERICH, ET AL., "Corticotropin-releasing factor receptors: An overview", <i>Exp. Clin. Endocrinol. Diabetes</i> , 1997, 65-82, Vol. 105, Johann Ambrosius Barth.	
CKS	24	P.J. GILLIGAN, ET AL., "Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents", <i>Journal of Medicinal Chemistry</i> , May 4, 2000, 1641-1660, Vol. 43, No. 9, American Chemical Society.	
CKS	25	C.A. MALTIN, ET AL., "Clenbuterol, a β -adrenoceptor agonist, increases relative muscle strength in orthopaedic patients", <i>Clinical Science</i> , 1993, 651-654, Vol. 84.	



Please type a plus sign (+) inside this box → [+]

PTO/SB08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 3 of 3

COMPLETE IF KNOWN	
Application Number	10/649,852
Confirmation Number	7224
Filing Date	August 27, 2003
First Named Inventor	Robert J. Isfort
Group Art Unit	
Examiner Name	
Attorney Docket Number	8448R

44	26	J.F. SIGNORILE, ET AL., "Increased Muscle Strength in Paralyzed Patients after Spinal Cord Injury: Effect of Beta-2 Adrenergic Agonist", <i>Arch Phys Med Rehabil</i> , 1995, 55-58, Vol. 76.	
44S	27	L. MARTINEAU, ET AL., "Salbutamol, a β_2 -adrenoceptor agonist, increases skeletal muscle strength in young men", <i>Clinical Science</i> , 1992, 615-621, Vol. 83.	
44S	28	MEDLER, S., "Comparative trends in shortening velocity and force production in skeletal muscles", <i>Am. J. Physiol Regulatory Integrative Comp Physiol</i> , 2002, Vol. 283, pp. R368-R378.	
44S	29	ROME, L.C., "The Design of Vertebrate Muscular Systems: Comparative and Integrative Approaches", <i>Clinical Orthopaedics and Related Research</i> , 2002, No. 403S, pp. S59-S76.	

EXAMINER

Shulamith H. Shabot

DATE CONSIDERED

9-22-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.